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Background: Rhodiola rosea (R. rosea) is grown at high altitudes and northern latitudes. Due to its purported
adaptogenic properties, it has been studied for its performance-enhancing capabilities in healthy populations and
its therapeutic properties in a number of clinical populations. To systematically review evidence of efficacy and
safety of R. rosea for physical and mental fatigue.
Methods: Six electronic databases were searched to identify randomized controlled trials (RCTs) and controlled
clinical trials (CCTs), evaluating efficacy and safety of R. rosea for physical and mental fatigue. Two reviewers
independently screened the identified literature, extracted data and assessed risk of bias for included studies.
Results: Of 206 articles identified in the search, 11 met inclusion criteria for this review. Ten were described as RCTs
and one as a CCT. Two of six trials examining physical fatigue in healthy populations report R. rosea to be effective
as did three of five RCTs evaluating R. rosea for mental fatigue. All of the included studies exhibit either a high risk
of bias or have reporting flaws that hinder assessment of their true validity (unclear risk of bias).
Conclusion: Research regarding R. rosea efficacy is contradictory. While some evidence suggests that the herb may
be helpful for enhancing physical performance and alleviating mental fatigue, methodological flaws limit accurate
assessment of efficacy. A rigorously-designed well reported RCT that minimizes bias is needed to determine true
efficacy of R. rosea for fatigue.Background
Rhodiola rosea (R. rosea) is a flowering biennial grown
in high latitude and altitude regions of the world. It has
been a part of traditional medicine systems in parts of
Europe, Asia and Russia for centuries. It has been pre-
scribed for cancer and tuberculosis in Mongolia [1],
given to newlyweds to boost fertility in Siberia [2], and
used by Vikings to increase endurance and physical
strength [3]. In Norway, it has even been used as food
and hair wash [4].
More recently R. rosea has received attention from the
scientific community for its potential therapeutic cap-
acity as an adaptogen. Adaptogen are “[most commonly]
natural herbal products which are non-toxic in normal
doses, produce a non-specific response, and have a nor-
malizing physiologic influence” [5]. Similarly, R. rosea* Correspondence: svohra@ualberta.ca
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reproduction in any medium, provided the orhas been referred to as an ergogenic aid, i.e. an herb used
to enhance physical and mental performance. Common
indications pertaining to the adaptogenic and ergogenic
capacity of R. rosea include performance enhancement, fa-
tigue reduction and alleviation of depression symptoms.
Existing reviews suggest a benefit in physical and mental
performance attributable to R. rosea, however such reviews
fail to critically appraise included literature [6,7]; some
reviews rely on Russian studies that are not accessible in
major international databases [8,9]. This systematic review
aims to rigourously synthesize and appraise available clin-
ical evidence of the efficacy of R. rosea for improving
physical and mental performance.Active constituents
Active constituents are biologically active components of
pharmacological formulations. While it is currently un-
clear which specific compound(s) in R. rosea are active
constituents, most preparations of R. rosea are standar-
dized to specific levels of marker compounds rosavin,
salidroside or both [8]. Rosavin is the only constituentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is common to most other Rhodiola species [10,11]. The
naturally occurring ratio of rosavins to salidrosides in R.
rosea is approximately 3:1 and R. rosea preparations
have been prepared to reflect this ratio [12].
Methods
Search strategy
This systematic review stemmed from a larger review pre-
pared for the Government of Alberta in 2007 for all po-
tential indications of Rhodiola rosea. This review includes
a subset of those studies examining R. rosea for fatigue.
The term “rhodiola rosea” and common synonyms (arctic
root, roseroot, rosenroot, golden root and hong jing tian)
were used to search the following electronic databases:
MEDLINE (1950 – July 2009), Cochrane Evidence Based
Medicine databases (1991 – July 2009), EMBASE (1988 –
July 2009), Alternative Medicine Database (AMED)
(1985 – July 2009), Natural Medicines Comprehensive
database (up to July 2009) and The International
Pharmaceutical Abstract Database (up to July 2009). The
detailed strategy for all databases can be found in the
Appendix.
Inclusion criteria
The inclusion criteria for included studies were as follows:
(i) study design: any clinical trial; (ii) population: any clin-
ical human population; (iii) intervention: Rhodiola rosea
alone or in combination with other compounds; (iv) con-
trol: any comparator was considered eligible; (v) out-
comes: mental or physical fatigue measured by any means.
Where validated instruments were used, this information
was collected.
Fatigue can be described as a pervasive sense of tired-
ness or lack of energy that is not related exclusively to
exertion [13]. Fatigue can result due to excess physical
or mental activity, sleep deprivation, and poor diet or
range of medical conditions including infection, and car-
diovascular, metabolic, connective tissue and endocrine
disorders [13]. Division of mental and physical fatigue is
arbitrary and often the two cannot be differentiated
[13-15]. As such, studies describing physical or men-
tal fatigue were both eligible for inclusion.
Due to the natural geographical distribution of the R.
rosea plant (i.e. Scandinavian countries, Russia and parts
of northern Asia), both English and non-English litera-
ture were considered. Non-English studies were trans-
lated into English.
Study selection and data extraction methods
Two authors (LS and SI) independently screened studies
identified using the search strategy for inclusion, first on
the basis of title and abstract and of those that were rele-
vant, the full texts were screened for eligibility. The sametwo authors independently extracted data from each
study using pre-developed data extraction forms. Discrep-
ancies between reviewers were discussed and resolved by
consensus. Authors of included studies were contacted to
confirm and answer questions about the data.
Data extraction items
Items for which data were extracted include: publication
year, country of publication, study design, population de-
scription, diagnostic criteria, age, intervention descrip-
tion, % salidrosides, % rosavins, control description,
dose, duration, frequency, run-in period length, washout
period length, follow-up period, number of participants
randomized and analysed in each group, effect measures
and measures of precision, outcome measurement tools,
author’s conclusions, description and number of adverse
events in each group.
Risk of bias assessment
Two reviewers (LS and SI) independently assessed the
risk of bias of each trial, following the domain-based
evaluation endorsed by the Cochrane Collaboration [16].
The domains are as follows: randomization, concealment
of allocation, blinding (of participants, personnel and
outcome assessors), incomplete outcome data (whether
investigators used an intention-to-treat analysis), select-
ive outcome reporting, and other factors.
In the first three domains, and answer of “Yes” means a
low risk of bias, “No” means there is a high risk of bias
and “unclear” means there is an uncertain risk of bias
(likely due to poor reporting). In the latter three domains,
responses mean the opposite - “yes” means high risk of
bias and “no” mean low risk of bias.
Analysis plan
We planned to report continuous outcomes as changes
from baseline and where possible, to compare the differ-
ence between R. rosea and control as mean differences
(MD) with 95% confidence intervals (CI). We planned to
convert dichotomous outcomes into risk ratios and 95%
CIs. Meta-analysis was planned where more than one
study provided data for a single outcome.
Results
Description of included studies
Two hundred and six unique articles were identified
from the search and 11 met final inclusion criteria. Of
those, 10 were described as randomized controlled trials
(RCT) [17-26] and one was a controlled clinical trial
(CCT) [24]. Six studies examined the effect of R. rosea
on physical performance and five assessed mental fa-
tigue. None of the studies examining R. rosea examining
physical or mental fatigue measured outcomes consist-
ently - no two studies reported the same outcomes. As
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studies are described in text below and Table 1.Risk of bias in trials of rhodiola rosea
As can be seen from Figure 1, the majority of studies in
each domain have an ‘unclear’ risk of bias in almost
every domain due to how they were reported. None of
the included studies are free of plausible bias (Figure 1),
which raises potential concern about the validity of their
results. In the domain of “other risk of bias”, six studies
reporting non-significant results have a low risk of bias
due to lack of sample size calculation [18,19,21,25,26],
one calculated a sample size but did not specify a pri-
mary outcome [24] and three reported the use of out-
come measurement tools that are not validated [19,24].Physical fatigue
Five RCTs and one CCT of R. rosea for enhancing phys-
ical performance were identified. Two trials examine a
R. rosea-only supplement, two examined R. rosea-strach
combined, and another two evaluate R. rosea combined
with cordyceps.R. Rosea as single ingredient versus placebo
A three arm double blind RCT compared the effect of R.
rosea (as a single ingredient) to placebo, or nothing [17].
The study examined muscle recovery in 30 adults by
measuring C-reactive protein (CRP) and creatinine kin-
ase (CK) levels in blood. Subjects underwent an exhaust-
ing physical exercise test on day 30 which consisted of
cycling at 20 W on a bicycle ergometer with power
increased by 10 W/min until volitional exhaustion (i.e.
subject could no longer pedal at 60 rpm). Findings indi-
cate that R. rosea significantly lowered CRP levels at 5
hours and 5 days after the test (p< 0.05) but that CK
levels were not significantly different between groups.
Adverse events were not reported.
A double-blind cross-over RCT examined the effect of
R. rosea on exercise performance in twelve male subjects
[25]. Subjects received R. rosea or identical placebo for
3 days before outcomes were measured by an exercise
test and another dose on the day of the test. A wash-out
period of 7 to 14 days separated cross-over to the oppos-
ite treatment. The primary outcome was muscle recov-
ery measured by ATP levels and secondary outcomes
were time to exhaustion and perceived exertion; all out-
comes were measured at baseline, during the exercise
test and during recovery. There was no significant differ-
ence between groups in Pi, phosphocreatine and ATP
levels, time to exhaustion and perceived exhaustion. Ad-
verse events and drop-outs were not mentioned.R. Rosea plus starch versus starch alone
One cross-over RCT and one CCT described in a single
report examined the acute and long-term effects, re-
spectively, of R. rosea on exercise performance [20]. In
both studies, endurance capacity was the primary out-
come and muscle strength, speed of limb movement, re-
action time and sustained attention were secondary
outcomes.
In the first study on acute effects, R. rosea combined
with starch or placebo was taken on each of 2 days [20].
One hour after ingestion on each day, outcomes were
measured while subjects underwent a physical function-
ing test. After a five day washout period, subjects
switched to the alternate treatment and performed the
same tests. Baseline measurements were not taken.
Three out of six parameters of endurance capacity (time
to exhaustion, O2 uptake and CO2 output) significantly
improved (p< 0.05) in the R. rosea group. There was no
difference between groups in any secondary outcomes.
After five days, authors stated that 12 subjects were
reassigned to intervention and control groups for the
long-term evaluation study. The long term study evalu-
ated subjects receiving same intervention and control as
in the acute study twice per day over a four week period
[20]. The same outcomes as in the acute study were
measured. Long term supplementation produced no sig-
nificant difference in any outcomes between treatment
groups; one participant on R. rosea dropped out during
long term supplementation for medical reasons unrelated
to the study protocol (reason not stated). One subject with
strong headaches during acute supplementation and one
with minor headaches during long term supplementation
were both on placebo. One subject experienced a minor
headache and another had insomnia during long term
supplementation of R. rosea. It is unclear why the long-
term study was not randomized.
R. Rosea plus cordyceps versus placebo
Two double blind RCTs conducted evaluate the effect of
R. rosea combined with other herbs on exercise perform-
ance [18,21]. Both studies were conducted by the same
group of authors using slightly different protocols and
populations. In both studies, intervention capsules were
described as every 3 capsules containing 300 mg of R.
rosea (standardized to 3.0% rosavins and 2.5% salidrosi-
desminimum), 1000 mg of Cordyceps sinensis, a Chinese
herb reported to improve circulation [27], and 800 mg
of the manufacturers ‘proprietary blend’ of substances
(undisclosed).
In one of the RCTs, 17 male were randomly assigned
to either the R. rosea-containing formulation or placebo
for 15 days [21]. Subjects took six capsules per day for
4 days (loading dose) then three capsules per day 11 days
(maintenance dose). Endurance capacity was measured
Table 1 Rhodiola rosea summary of clinical evidence
PHYSICAL PERFORMANCE
R. rosea single ingredient versus placebo
Study ID Design Population Intervention/Control Outcome(s)
Abidov
2004
DB RCT 36 male and female non-smokers
between 21–24 y.o.a.
Int: 340 mg RR extract containing
30 mg active RR (including rosavin)
CRP blood-levels 5 h and 5 days after
exercise were less than placebo and
control.
(Russia) Con(1): placebo
Con(2): no intervention; CK levels in blood same across groups
after 5 hours, but reduced after 5 days in
only R. rosea group.Regimen: for 30 days before and 6 days
after exhausting physical exercise.
Walker
2007
DB CO RCT 12 resistance-trained males
(19–39 y.o.a.)
Int: 1500 mg/day RR for 3 days before
exercise test + 1000 mg on day of test
Con: placebo;
No significant differences between
groups in measures of ATP kinetics and
exhaustion.
(US)
Regimen: RR followed by 7–14 days
washout and same dosing regimen of
placebo OR treatment in reverse order
R. rosea Plus starch versus placebo
De Bock
2004a
DB CO RCT 24 healthy physically active male
(21.8 ±0.3 y.o.a) and female
(20.2 ± 0.3 y.o.a.) students
Int:100 mg RR +250 mg starch RR ‘significantly’ delayed time to
exhaustion, peak O2 uptake and CO2
output.
(Belgium) Con: 350 mg starch




DB CCT Int:100 mg RR +250 mg starch significantly higher blood lactate levels
after 4-wk intake.
(Belgium) Con: 350 mg starch
Regimen: RR or placebo twice/day over
4 weeks
Overall, no change in muscle strength,
speed of limb movement, reaction time,
sustained attention.
R. rosea plus Cordyceps versus Placebo
Earnest
2004 (US)
DB RCT 17 male competitive cyclists Int: loading dose of 6 capsules/day for
4 days (every three capsules contain
1000 mg Cordyceps sinensis+ 300 mg RR)
then maintenance dose of 3 capusles/
day for 11 days
No significant difference between or
within Tx groups in peak and subpeak
exercise variables.int: 31.6 ± 2.8 (SE) y.o.a.




DB RCT 8 males between 18–34 y.o.a. Int: loading dose of 6 capsules/day for
6 days (every three capsules contain
1000 mg Cordyceps sinensis+ 300 mg RR)
then maintenance dose of 3 capsules/
day for 7 days
After pre-post endurance test no
significant difference between




Study ID Design Population Intervention/Control Outcome(s)
Olsson
2008
DB RCT 60 male and female (20–55 y.o.a)
with fatigue syndrome
Int: 4 Verum tablets/day for 28 days
(each tablet contain 144 mg Rhodiola
extract SHR-5)
Significant improvement in fatigue
scores (measured by Pines burnout
scale), and significant improvement in
two of five CCPT II indices
Con: identical placeboint: 41.0 ± 7.9 y.o.a
con: 42.1 ± 8.5 y.o.a.
Darbinyan
2000
DB CO RCT 56 male and female physicians
on night duty
Group A: Standardized extract of 170 mg
RR for 2 weeks; 2 week Washout;
2 weeks identical placebo. Group B:
treatment in reverse order
Significant improvement in total fatigue
score after two weeks on RR;
(Armenia) Group A: 25.5 ± 3.8 y.o.a.
Group B: 27.3 ± 2.9 y.o.a.
Shevstov
2003
DB RCT 121 male military cadets 19–21
y.o.a.
Int: 41 subjects – 2 capsules (185 mg
each) RR.
Total antifatigue index scores
significantly lower in both RR groups
than placebo (p< 0.0001).
(Russia) 20 subjects – 3 capsules RR
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“statistically significant beneficial
physiological effect in the RR groups
versus the placebo group”
Con: 40 subjects – identical placebo






40 Male students from India
17–19 y.o.a.
Int: 2 x 50 mg RR tablets twice/day for
20 days
Non-significant improvement in physical
work and mental capacity. Significant
improvement in general well-being





RCT 60 male students from India
(17–18 y.o.a.)
Int: 660 mg/day for 20 days RR; Con(1):
placebo; Con(2): nothing
Measures of subjective self-evaluation,
psychological fatigue, situational anxiety,
motivation, precision of motor function,
process of excitement and need for rest
are significantly different within RR
group (<0.05). Mean changes in mental
work capacity and neuromotor function
are not significantly different between
groups.
Abbreviations: RR Rhodiola rosea, DB double-blind, RCT Randomized controlled trial, CCT Controlled clinical trial, CO cross-over, Int Intervention, Con Control, DO
Drop-outs, AE Adverse events.
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power output, time to exhaustion and peak heart rate,
which were measured at the beginning and end of the
study period. The authors found that the herbal formu-
lation did not have any significant effect on exercise en-
durance or capacity. Adverse events were not reported.
The second study involving eight male cyclists rando-
mized to either R. rosea-containing formulation (33.0±12.6)
years) or placebo (23.8± 2.9 years), followed the same
protocol as above, however the study period was only
13 days – 6 days of the loading dose and 7 days of the
maintenance dose [18]. Respiratory parameters were mea-
sured in the participants. This study also found no signifi-
cant difference in outcomes between groups. There were
no drop outs; adverse events were not mentioned.
Mental fatigue
A double blinded RCT assessed the efficacy of a R. rosea
extract, SHR-5, for stress related fatigue [22]. Sixty sub-
jects were randomized to receive 576 mg of R. rosea
preparation or placebo per day for 28 days. Mental fatigue,
measured by the Pines burnout scale, was the primary
outcome. Other outcomes evaluated were depression
(Montgomery-Asberg Depression Rating Scale, MADRS),
quality of life (Medical Outcomes Study Short form
36-item questionnaire, SF-36), attention (Conners’
Computerized Continuous Performance Test II, CCCPT
II) and “anti-fatigue” effect (saliva cortisol response after
awakening). All outcomes were measured before and after
the treatment period. The Pines burnout scale scores
(p=0.047) and two out of five indices of CCCPT II
(p=0.02, p=0.001) improved in favour or R. rosea. While
investigators conclude that the treatment appears to have
beneficial effect, they report excluding follow-up data for
at least 5 participants due to physical loss of data and
protocol deviations. Per-protocol analyses (i.e. analysis of
only participants who followed the protocol for theentirety of the study) may overestimate treatment effect if
the reasons for incomplete data are related to the treat-
ment effect [28,29] – in this case, it is not explicitly stated
what “protocol deviations” occurred. No adverse effects
occurred during the study period.
R. rosea for non-specific fatigue was evaluated in a
double-blind crossover RCT in 56 Armenian physicians
[19]. Participants were randomized to either 170 mg R.
rosea (standardized to 2.6% salidroside) or placebo. The
study period lasted for two weeks followed by a two-
week wash-out period, after which participants were
crossed over for two weeks. The primary outcome was
fatigue, measured using a fatigue index developed for
use in this study; the tool does not appear to be vali-
dated. Measurements were carried out before and after
the treatment period. Authors state that they found a
significant improvement in the fatigue index after two
weeks of R. rosea supplementation, but only present data
for the 5 individual test scores. Since we are unable to
replicate and confirm their analysis, findings of this
study must be interpreted as inconclusive. Authors indi-
cate that no adverse events occurred; whether or not
anyone dropped out of the study was not reported.
A double-blinded RCT conducted in Russia evaluated
the effect of two different single doses of R. rosea on
mental fatigue [23]. Subjects were randomized to take R.
rosea or placebo. A non-treatment group was also
included, however subjects were not randomized into
this group and comparisons against this group will not
be considered in this review. The intervention was taken
at 4:00 am while participants were on an overnight shift.
Capacity for mental work, measured using a fatigue
index of unknown origins and pulse pressure and rate
were evaluated before night duty and one hour after tak-
ing the study medication. A self-report questionnaire
evaluating general well-being was completed after taking
the study medication. The fatigue index was comprised
Figure 1 Risk of bias assessment in included studies.
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ory and perception of order. Improvements in favour of
both doses of R. rosea were apparent in the fatigue index
(p< 0.001); no significant differences between groups oc-
curred for other outcomes. The method of randomization
was unclear. One subject in the placebo group experi-
enced hypersalivation; whether or drop-outs occurred was
not reported.
A double-blinded RCT pilot study examined the effect
of a repeated low dose of R. rosea on foreign students’
mental and physical well-being during their examination
period [24]. Subjects were randomized into 2 groups to
receive either 100 mg R. rosea once per day or identicalplacebo for 20 days. Hand-eye coordination (maze test),
motoric speed (tapping test), mental work capacity (cor-
rection of text test), fatigue and well-being (self-evaluation
questionnaire), heart rate and physical work capacity (bi-
cycle ergometer test) were assessed. Significant improve-
ments were observed in hand-eye coordination (p< 0.01),
mental fatigue and general-well being (p< 0.01) in favour
of R. rosea. Students on placebo had a significantly higher
heart rate (p< 0.05). Drop-outs and adverse events were
not reported by authors.
Another RCT conducted by the same group examined
60 male students in their first year of study at a Russian
high school [26]. Students were randomized into 3
groups to receive either of Rhodaxon (R. rosea extract
with no ethyl alcohol per day; proportions of active con-
stituents not given), placebo or nothing for 20 days. Par-
ticipants underwent the same tests for mental and
physical capacity as above as well as a psychophysiological
test [Lusher test [30]] to determine level of anxiety, psy-
chological fatigue and need to rest. A comparative analysis
between groups was not conducted leaving the effect of R.
rosea indeterminable. Adverse events and drop-outs were
not reported.
Adverse effects
Out of 446 subjects examined in the 11 included clinical
studies, five adverse events were mentioned in three
studies. Two subjects on 200 mg of R. rosea over a 4-
week period each experienced a minor and serious head-
ache [24]; one subject on placebo over a 2-day treatment
period experienced a minor headache and another had
insomnia [20]. Another subject on placebo experienced
hypersalivation [23]. There appear to be few side effects
associated with R. rosea supplementation; those identi-
fied are of a mild nature.
Discussion
Even though 10 of the 11 included studies are RCTs,
there is insufficient evidence to evaluate the effectiveness
of Rhodiola rosea on physical or mental fatigue. While
RCTs are the modern day gold standard for assessment
of efficacy of medical interventions, none of the included
RCTs appeared to be compliant with the CONSORT
(Consolidated Standards of Reporting Trials) Statement,
an internationally agreed-upon set of RCT reporting
guidelines [31]. In addition, appraisal using the Cochrane
Collaboration’s new tool for assessing bias in RCTs, indi-
cates a largely unclear or high risk of bias within
included studies.
Of the five RCTs of R. rosea for enhancing mental per-
formance identified, three indicated that the herb may
be effective in improving overall health in a mentally
fatigued population. However, two of these studies did
not appear to use validated measures of fatigue, making
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remaining studies offered inconclusive or negative results.
Further rigorous RCTs are required in order to determine
the effect of R. rosea on mental fatigue.
R. rosea has demonstrated a very low occurrence of side
effects demonstrating a low clinical toxicity. Although no
contraindications with other herbal or prescription medi-
cations have been identified, it is important to consider
that R. rosea may have an additive effect with other sub-
stances exhibiting stimulant properties [32]. Like many
natural health products, the likelihood of adequate report-
ing of adverse events may be lower than conventional
medications [33].
Clinical studies report R. rosea-only products ranging
in dose from 50 mg to 660 mg per capsule, to a max-
imum of 1500 mg/day, suggesting a large margin of
safety. Studies reporting a positive effect of R. rosea on
physical performance reported doses of 200 mg/day and
680 mg/day and those reporting a positive effect on
mental fatigue reported doses between 100–576 mg/day.
Limitations
It is not possible to know the sole effect of R. rosea from
combination interventions. However our goal was to be
comprehensive in our approach, and these studies were
included in case they provided interesting hypothesis
generating questions for future research.
No studies in this review specifically included pediatric
populations or pregnant or lactating women. As well,
pregnant or lactating women were explicitly excluded
from the majority of clinical studies. No indications have
been identified which are specifically relevant to either of
these populations, nor have reports of toxicity or adverse
events. Overall, due to the paucity of clinical studies in-
cluding these populations, no dosage recommendations
can be made until further studies have been conducted
which evaluate the safety and/or toxicity of R. rosea in
children and pregnant or lactating women.
Conclusion
The current evidence for efficacy of R. rosea is contradict-
ory and inconclusive. Methodologically rigorous RCTs
must be designed to overcome these serious threats to in-
ternal validity. Such studies will help inform policy-
makers, health care providers, and the public about the ef-
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registry word, abstract, trade name/generic name]
9. lignum rhodium.mp. [mp= title, subject heading
word, registry word, abstract, trade name/generic name]
10. sedum rhodiola.mp. [mp= title, subject heading
word, registry word, abstract, trade name/generic name]
11. sedum rosea.mp. [mp= title, subject heading word,
registry word, abstract, trade name/generic name]
12. hong jing tian.mp. [mp= title, subject heading
word, registry word, abstract, trade name/generic name]
13. or/1-12
14. limit 13 to human
Embase
1. exp Rhodiola Extract/or exp Rhodiola/or exp Rhodiola
Rosea Extract/





7. rosenroot.mp. [mp= title, abstract, subject headings,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer name]
8. rosen root.mp. [mp= title, abstract, subject head-
ings, heading word, drug trade name, original title, de-
vice manufacturer, drug manufacturer name]
9. rodia riza.mp. [mp= title, abstract, subject headings,
heading word, drug trade name, original title, device
manufacturer, drug manufacturer name]
10. lignum rhodium.mp. [mp = title, abstract, sub-
ject headings, heading word, drug trade name, ori-
ginal title, device manufacturer, drug manufacturer
name]
11. sedum rhodiola.mp. [mp= title, abstract, subject
headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer name]12. sedum rosea.mp. [mp= title, abstract, subject head-
ings, heading word, drug trade name, original title, de-
vice manufacturer, drug manufacturer name]
13. hong jing tian.mp. [mp= title, abstract, subject
headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer name]
14. or/1-13
15. limit 14 to human
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